Table 2.
Clinical trials of toxin-conjugated antibodies for AML.
| NCI Clinical Trial and Phase | Target | Agent(s) | Inclusion Criteria | Estimated Start and End Dates | Status |
|---|---|---|---|---|---|
| NCT03374332 Phase 2 | CD33 | gemtuzmab ozogamicin | ≥18 years of age with R/R AML | June 2019 March 2021 |
Not yet recruiting |
| NCT03737955 Phase 2 | CD33 | gemtuzmab ozogamicin | ≥2 years of age with AML in CR with MRD after induction chemotherapy | November 2018 August 2021 | Recruiting |
| NCT03531918 Phase 1/2 | CD33 | gemtuzmab ozogamicin in combination with GCLAM | ≥18 years of age with untreated “high-grade” myeloid neoplasm (≥10% Blasts in blood or BM) or AML, exluding APL | September 2018 July 2025 | Recruiting |
| NCT02674763 Phase 1 | CD33 | IMGN779 | ≥18 years of age with R/R AML | March 2016 December 2019 | Recruiting |
| NCT03386513 Phase 1 | CD123 | IMGN632 | ≥18 years of age with R/R CD123 + AML and other CD123 + malignancies | January 2018 February 2021 |
Recruiting |
| NCT02864290 Phase 1 | FLT3 | ASP1235 (AGS62P1) | ≥18 years of age with R/R AML | November 2016 January 2024 |
Recruiting |
| NCT03957915 Phase 1 | CD71 | INA03 | ≥18 years of age R/R AML, ALL, or MPAL with ≥ 20% CD71 positive blasts | September 2019 November 2021 | Active, not recruiting |
| NCT01830777 Phase 1 | CD30 | Brentuximab vedotin in combination with Mitoxantrone, Etoposide, and Cytarabine | ≥18 years of age with CD30 + relapsed AML |
May 2013 December 2019 |
Active, not recruiting |
NCI: National Cancer Institute; AML: Acute Myeloid Leukemia; R/R: Relapsed/Refractory; MRD: Measurable Residual Disease; BM: Bone Marrow; GCLAM: Granulocyte-Colony Stimulating Factor, Cladribine, Cytarabine and Mitoxantrone.